Fluorine F 18 FEQA in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer and in Healthy Participants

• Sponsor: Jonsson Comprehensive Cancer Center (Other)
• Overall Status: Terminated
• CT.gov ID: NCT00444223
• Collaborator: (none)
• Enrollment: 3
• Location: 1
• Arm: 1
• Actual Duration (Months): 48.4
• Patients Per Site Per Month: 0.1

Study Details

Study Description

Brief Summary

RATIONALE: Fluorine F 18 FEQA may be an effective radioactive drug to use with positron emission tomography (PET) scans.

PURPOSE: This clinical trial is studying the use of fluorine F 18 FEQA in patients with stage III or stage IV non-small cell lung cancer and in healthy participants.

Condition or Disease	Intervention/Treatment	Phase
Lung Cancer	Procedure: fluorine F 18 FEQA + positron emission tomography	N/A

Detailed Description

OBJECTIVES:

• Determine the biodistribution of fluorine F 18 FEQA in patients with stage III or IV non-small cell lung cancer (NSCLC) and in healthy participants.

• Determine whether fluorine F 18 FEQA can be used as an imaging agent with positron emission tomography in patients with stage III or IV NSCLC.

OUTLINE: This is a pilot study.

Patients and healthy participants receive fluorine F 18 FEQA IV and then undergo whole-body dynamic scans comprising positron emission tomography.

Blood is collected during and after imaging to measure radioactivity.

PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.

Study Design

• Study Type: Interventional
• Actual Enrollment: 3 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Diagnostic
• Official Title: The Biodistribution of N-{4-[3'-[F-18] Fluoroethylphenyl)Amino]-6-quinazolinyl}-Acrylamide ([F-F18]FEQA) in Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC) and in Healthy Subjects: A Pilot Study
• Actual Study Start Date: May 4, 2004
• Actual Primary Completion Date: May 15, 2008
• Actual Study Completion Date: May 15, 2008

Arms and Interventions

Arm	Intervention/Treatment
Experimental: fluorine F 18 FEQA + positron emission tomography	Procedure: fluorine F 18 FEQA + positron emission tomography

Outcome Measures

Primary Outcome Measures

1. Biodistribution of fluorine F 18 FEQA [1 day]

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Inclusion Criteria:

• Must meet 1 of the following criteria:

• Diagnosis of non-small cell lung cancer by CT scan, bone scan, or biopsy

• Stage III or IV disease

• Clinically assessed with

• Healthy participant

Exclusion Criteria:

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Jonsson Comprehensive Cancer Center at UCLA	Los Angeles	California	United States	90095-1781

Sponsors and Collaborators

• Jonsson Comprehensive Cancer Center

Investigators

• Study Chair: Johannes Czernin, MD, Jonsson Comprehensive Cancer Center

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Jonsson Comprehensive Cancer Center
• ClinicalTrials.gov Identifier: NCT00444223
• Other Study ID Numbers: CDR0000529363; UCLA-0304039-01
• First Posted: Mar 7, 2007
• Last Update Posted: Aug 5, 2020
• Last Verified: Feb 1, 2016

• Keywords provided by Jonsson Comprehensive Cancer Center: stage IIIA non-small cell lung cancer; stage IIIB non-small cell lung cancer; stage IV non-small cell lung cancer
• Additional relevant MeSH terms: Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Fluorides

Study Results

No Results Posted as of Aug 5, 2020